Table 3. Brain region metabolite analysis following peripheral inflammation (% saline).
| Metabolite (% saline) |
Brain region |
ANOVA,P-value | |||
|---|---|---|---|---|---|
| Dorsal hippocampus | Ventral hippocampus | Central amygdala | Nucleus accumbens | ||
| Tryptophan | 126.14 (4.2) | 128.78 (10.1) | 183.33 (15.1) | 148.33 (18.0) | P<0.01 |
| Kynurenine | 259.03 (19.8) | 254.37 (14.6) | 344.91 (26.7) | 356.87 (70.5) | n.s. |
| 3-HK | 146.92 (16.5) | 127.98 (14.7) | 170.49 (25.2) | 169.22 (15.0) | n.s. |
| 3-HAA | 137.72 (11.1) | 99.30 (12.6) | n.d. | n.d. | P<0.05 |
| KA | 133.54 (20.1) | 109.07 (25.9) | 323.49 (110.3) | 391.40 (93.6) | P<0.01 |
| XA | 268.78 (37.2) | 201.84 (28.4) | 200.66 (29.0) | 224.32 (38.5) | n.s. |
Abbreviations: ANOVA, analysis of variance; i.p., intraperitoneal; KA, kynurenic acid; LC/MS, liquid chromatography/mass spectrometry; LPS, lipopolysaccharide; n.d., metabolite concentrations not reported because of high number of samples that were not detected with the LC/MS method utilized to analyze the samples; n.s., no significant difference; XA, xanthurenic acid; 3-HAA; 3-hydroxyanthranilic acid; 3-HK, 3-hydroxykynurenine.
Kynurenine metabolites (tryptophan, kynurenine, KA, 3-HK and 3-HAA) were quantified (μM) by LC/MS in relevant brain regions (dorsal hippocampus, ventral hippocampus, central amygdala and nucleus accumbens) following i.p. treatment with saline or LPS (0.5 mg kg−1). Concentration values were then used to calculate % saline values, which are presented in the table as mean (s.e.m.). n=6–12 samples per treatment
.
Significant differences are reported as: *P<0.05–0.01; **P<0.01–0.001; ***P<0.001.